Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Bio Sequence
2 min read
A Detailed Approach to Locating Patent Information for Your Specific Antibody Sequence
20 September 2023
To acquire patent data related to a delineated antibody sequence, the Patsnap Bio Sequence Database is an optimal resource for conducting a systematic search.
Drug Insights
4 min read
Decoding Baicalin: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
20 September 2023
This article summarized the latest R&D progress of Baicalin, the Mechanism of Action for Baicalin, and the drug target R&D trends for Baicalin.
Latest Hotspot
3 min read
The initiation patient treatment in Phase 2 clinical trials of Bempikibart for Alopecia Areata has been announced by Q32 Bio and Horizon Therapeutics plc
20 September 2023
IQ32 Bio and Horizon Therapeutics initiated a Phase 2 trial for bempikibart's effectiveness against severe adult alopecia areata.
Drug Insights
4 min read
Deep Scientific Insights on Artesunate's R&D Progress
20 September 2023
This article summarized the latest R&D progress of Artesunate, the Mechanism of Action for Artesunate, and the drug target R&D trends for Artesunate.
Valuable Targets
4 min read
Progress in the Research of COX-1 Inhibitors
20 September 2023
Cyclooxygenase, also known as Prostaglandin-endoperoxide Synthase, is a bifunctional enzyme with both cyclooxygenase and peroxidase activity.
Drug Insights
4 min read
An In-depth Analysis of Amobarbital's R&D Progress and Mechanism of Action on Drug Target
20 September 2023
This article summarized the latest R&D progress of Amobarbital, the Mechanism of Action for Amobarbital, and the drug target R&D trends for Amobarbital.
Latest Hotspot
3 min read
RS Oncology Reports New Preclinical Evidence Show RSO-021 Could Halt and/or Revert the Advancement of Severe Mesotheliomas
20 September 2023
At the 2023 IASLC World Lung Cancer Conference in Singapore, RS Oncology shared a first-of-its-kind PRX3 inhibitor, RSO-021's potential to combat swift mesothelioma tumor progression.
Drug Insights
4 min read
Salicylamide: Detailed Review of its Transformative R&D Success
20 September 2023
This article summarized the latest R&D progress of Salicylamide, the Mechanism of Action for Salicylamide, and the drug target R&D trends for Salicylamide.
Valuable Targets
4 min read
Progress in the Research of COMT Inhibitors
20 September 2023
Catechol O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of endogenous neurotransmitters, xenobiotics, and hormones with catechol structures.
Drug Insights
4 min read
Decoding Vilobelimab: A Comprehensive Study of its R&D Trends
19 September 2023
This article summarized the latest R&D progress of Vilobelimab, the Mechanism of Action for Vilobelimab, and the drug target R&D trends for Vilobelimab.
Latest Hotspot
3 min read
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
19 September 2023
InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.
Drug Insights
4 min read
Deep Scientific Insights on Vandetanib's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Vandetanib, the Mechanism of Action for Vandetanib, and the drug target R&D trends for Vandetanib.